In: Basic Research in Cardiology, 2015, vol. 110, no. 1, p. 1-17
|
In: Interactive CardioVascular and Thoracic Surgery, 2018, vol. 26, no. 6, p. 977-984
|
In: Shock, 2020, vol. 53, no. 5, p. 653–665
Objective: Activation of the constitutive nuclear and mitochondrial enzyme poly (ADP- ribose) polymerase (PARP) has been implicated in the pathogenesis of cell dysfunction, inflammation, and organ failure in various forms of critical illness. The objective of our study was to evaluate the efficacy and safety of the clinically approved PARP inhibitor olaparib in an experimental model of...
|
In: American Journal of Respiratory Cell and Molecular Biology, 2020, vol. 63, no. 5, p. 571–590
PARP1, the major isoform of a family of ADP-ribosylating enzymes, has been implicated in the regulation of various biological processes including DNA repair, gene transcription, and cell death. The concept that PARP1 becomes activated in acute lung injury (ALI) and that pharmacological inhibition or genetic deletion of this enzyme can provide therapeutic benefits emerged over 20 years ago....
|
In: Critical Care, 2020, vol. 24, no. 1, p. 318
|
In: Pharmacological Research, 2019, vol. 145, p. 104263
Poly(ADP-ribose) polymerase (PARP) is involved in the pathogenesis of cell dysfunction, inflammation and organ failure during septic shock. The goal of the current study was to investigate the efficacy and safety of the clinically approved PARP inhibitor olaparib in experimental models of oxidative stress in vitro and in sepsis in vivo. In mice subjected to cecal ligation and puncture (CLP)...
|
In: Heart Failure Reviews, 2014, vol. 19, no. 6, p. 815-824
|
In: Intensive Care Medicine, 2009, vol. 35, no. 7, p. 1297-1304
|
In: Cardiovascular Research, 2008, vol. 78, no. 2, p. 274-285
|
In: Journal of Infectious Diseases, 1998, vol. 177, no. 1, p. 127-132
|
